Wuxi Apptec China
Senior Principle Scientist and Sd
Md Anderson Cancer Center Jun 2010 - Nov 2013
Research Scientist
Mdacc Jan 2006 - Jan 2010
Senior Research Assistant
Kyushu University Jan 2001 - Jan 2002
Research Scientist
Shenyang Humming Institute of Natural Products Jan 1996 - Jan 1998
Director
Education:
Baylor College of Medicine 2003 - 2006
Shenyang Pharmaceutical University 2001 - 2001
Doctorates, Doctor of Philosophy, Pharmaceutical Science
Shenyang Pharmaceutical University 1991 - 1991
Master of Science, Masters
Jilin University 1982 - 1986
Bachelors, Bachelor of Science, Chemistry
Skills:
Molecular Biology Biochemistry Life Sciences Cell Culture Hplc Cell Biology Cancer Cell In Vitro Protein Chemistry Purification Pharmacology Lifesciences High Throughput Screening Lc Ms In Vivo
Name / Title
Company / Classification
Phones & Addresses
Shaoyu Yan Manager, Director
BESDONE LLC Business Services at Non-Commercial Site
Jack A. Roth - Houston TX, US David Stewart - Ottawa, CA Charles Lu - Houston TX, US Ignacio I. Wistuba - Houston TX, US Shaoyu Yan - Pearland TX, US Maria I. Nunez - Houston TX, US
A method for predicting a subject's response to a TUSC2 therapy is provided. In particular, a subject's response is predicted based on the proportion of cancers cells that are apoptotic. Also provided is a method of treating a subject previously predicted to have a favorable response with a TUSC2 therapy. Methods for treating cancer by administration of a TUSC2 therapeutic in conjunction with an EGFR inhibitor and/or a protein kinase inhibitor are also disclosed. Kits and reagents for use in TUSC2 therapy are provided.
- Austin TX, US David STEWART - Ottawa, CA Charles LU - Houston TX, US Ignacio I. WISTUBA - Houston TX, US Shaoyu YAN - Pearland TX, US Maria I. NUNEZ - Houston TX, US
Assignee:
Board of Regents, The University of Texas System - Austin TX
A method for predicting a subject's response to a TUSC2 therapy is provided. In particular, a subject's response is predicted based on the proportion of cancers cells that are apoptotic. Also provided is a method of treating a subject previously predicted to have a favorable response with a TUSC2 therapy. Methods for treating cancer by administration of a TUSC2 therapeutic in conjunction with an EGFR inhibitor and/or a protein kinase inhibitor are also disclosed. Kits and reagents for use in TUSC2 therapy are provided.
- Austin TX, US David STEWART - Ottawa, CA Charles LU - Houston TX, US Ignacio I. WISTUBA - Houston TX, US Shaoyu YAN - Pearland TX, US Maria I. NUNEZ - Houston TX, US
Assignee:
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM - Austin TX
A method for predicting a subject's response to a TUSC2 therapy is provided. In particular, a subject's response is predicted based on the proportion of cancers cells that are apoptotic. Also provided is a method of treating a subject previously predicted to have a favorable response with a TUSC2 therapy. Methods for treating cancer by administration of a TUSC2 therapeutic in conjunction with an EGFR inhibitor and/or a protein kinase inhibitor are also disclosed. Kits and reagents for use in TUSC2 therapy are provided.
- Austin TX, US David STEWART - Ottawa, CA Charles LU - Houston TX, US Ignacio I. WISTUBA - Houston TX, US Shaoyu YAN - Pearland TX, US Maria I. NUNEZ - Houston TX, US
Assignee:
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM - Austin TX
International Classification:
A61K 9/127 A61K 31/517 C07K 14/47 A61K 38/17
US Classification:
424450, 514 44 R, 514 189, 5142664
Abstract:
A method for predicting a subject's response to a TUSC2 therapy is provided. In particular, a subject's response is predicted based on the proportion of cancers cells that are apoptotic. Also provided is a method of treating a subject previously predicted to have a favorable response with a TUSC2 therapy. Methods for treating cancer by administration of a TUSC2 therapeutic in conjunction with an EGFR inhibitor and/or a protein kinase inhibitor are also disclosed. Kits and reagents for use in TUSC2 therapy are provided.